Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Trial to Validate the Safety and Efficacy of Zabinostat (CXD101) Monotherapy in Patients with Multiple Tumour Types and Peripheral T-cell lymphoma (PTCL)

Next Previous
Search
Trial Profile

A Phase Ib/II Trial to Validate the Safety and Efficacy of Zabinostat (CXD101) Monotherapy in Patients with Multiple Tumour Types and Peripheral T-cell lymphoma (PTCL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zabinostat (Primary)
  • Indications Peripheral T-cell lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nuance Biotech

Most Recent Events

  • 05 Jan 2023 According to a Celleron Therapeutics media release, Celleron Therapeutics has merged with the Argonaut Therapeutics to form IngenOx Therapeutics (www.ingenox.com).
  • 29 Jun 2022 According to a Celleron Therapeutics media release, the company expect to initiate this trial in 2022.
  • 02 Mar 2020 According to a Celleron Therapeutics media release, a peripheral T-cell lymphoma (PTCL) Phase II trial will start in 2020 in China.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top